Poster Programme

Poster Session 1
Monday 5 September 2016
16:30-18:30

Human vaccines - infectious diseases	
[P1.01]	**Evaluation of the highly-conserved nucleoprotein as target antigen for AAV-based broadly-protective influenza vaccines** K. Fiddeke*, I. Sipo, M. Budt, T. Wolff, N. Bannert, S. Norley, *Robert Koch Institute, Germany*
[P1.02]	**Impact of Uro-vaxom on HNP1-3 and lactoferrin of peripheral blood** E.A. Akhmatova[1], V.G. Khomenkov[1], E.V. Volkova[1,2], N.K. Akhmatova*[1], O.V. Lebedinskaya[1], T.S. Perepanova[1,2], V.V. Zverev[1], *[1]FGBNU Mechnikov Research Institute for Vaccines and Sera, Russia, [2]Lopatkin NA Institute of Urology and Interventional Radiology, Russia*
[P1.03]	**Immunological and biochemical characterizations of Coxsackievirus A6 and A10 viral particles** C.C. Liu*[1], M.S. Guo[1], S.R. Wu[2], H.Y. Lin[1], Y.T. Yang[1], W.C. Liu[1], Y.H. Chow[1,3], D.B. Shieh[2], J.R. Wang[2], P. Chong[1,3], *[1]National Health Research Institutes, Taiwan, [2]National Cheng Kung University, Taiwan, [3]China Medical University, Taiwan*
[P1.04]	**Investigating lyssavirus glycoprotein antigenicity and neutralisation** J.S. Evans[1,2], D. Selden[1], E. Wright[3], D.L. Horton[5], G. Wu[1], A.J. Easton[2], A.R. Fooks*[1,4], A.C. Banyard[1], *[1]Animal and Plant Health Agency, UK, [2]University of Warwick, UK, [3]University of Westminster, UK, [4]University of Liverpool, UK, [5]University of Surrey, UK*
[P1.05]	**Influenza vaccines: effects on immune cells** N.K. Akhmatova*, E.A. Khromova, E.A. Akhmatova, I.A. Semochkin, S.A. Skhodova, Y.N. Troinich, M.P. Kostinov, V.V. Zverev, *FGBNU Mechnikov Research Institute for Vaccines and Sera, Russia*
[P1.06]	**Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans** K.L. Mansfield[1,2], N. Andrews[3], H. Goharriz[1], T. Goddard[1], L.M. McElhinney[1,2], K.E. Brown[3], A.R. Fooks*[1,4], *[1]Animal and Plant Health Agency, UK, [2]University of Liverpool, UK, [3]Public Health England, UK, [4]University of London, UK*
[P1.07]	**Evaluation of protective efficacy induced by virus-like particles containing Trichinella spiralis excretory-secretory (ES) protein in mice** S.H. Lee, S.S. Kim, F.S. Quan*, *Kyung Hee University Kyung Hee University, Republic of Korea*
[P1.08]	**Study on standardization of immunogenicity testing method for vaccines** H.K. Kang*, E.J. Kwon, B.G. Kim, C.W. Choi, S.J. Park, S.Y. Kim, S.H. Hong, J.O. Kim, *NIFDS MFDS, Republic of Korea*
[P1.09]	**Recombinant dengue envelope protein domain III incorporated with a live-attenuated vaccine priming strategy** H.H. Lin*[1], M.J. Tsai[1], H.C. Wu[2], S.C. Wu[1], *[1]National Tsing Hua University, Taiwan, [2]Academia Sinica, Taiwan*
[P1.10]	**Influenza vaccination coverage in overseas born older adults in Australia** S. Karki*[1], A. Dyda[1], A. Newall[1], A. Heywood[1], C.R. MacIntyre[1], P. McIntyre[2], E. Banks[3], B. Liu[1,4], *[1]University of New South Wales, Australia, [2]National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Australia, [3]Australian National University, Australia, [4]The Sax Institute, Australia*
[P1.11]	**Enhancement of avian influenza DNA vaccine potency using a conventional adjuvant 'alum phosphate'** H. Yi*, K-W. Seo, E.Y. Jang, M-S. Lee, J. Cho, J-Y. Lee, K. Kim, *Centers for Disease Control & Prevention, Republic of Korea*
[P1.12]	**Prime-boost immunization strategies against dengue virus** D.Y. Chao*, J.U. Galula, C.Y. Yang, *National chung-Hsing University, Taiwan*
[P1.13]	**Effectiveness in preventing varicella and safety of combined MMRV vaccine in the pediatric population of a large Italian region** D. Martinelli*, F. Fortunato, M.G. Cappelli, R. Prato, *University of Foggia, Italy*
[P1.14]	**Influenza vaccine effectiveness during 2015-2016 influenza season: a hospital-based case-control study in Lithuania** M. Kuliese*[1], L. Jancoriene[2], R. Grimalauskaite[1], B. Zablockiene[2], G. Damuleviciene[1], D. Velyvyte[1], V. Lesauskaite[1], A. Ambrozaitis[2], A. Mickiene[1], G. Gefenaite[1], *[1]Lithuanian University of Health Sciences, Lithuania, [2]Vilnius University, Lithuania*

[P1.15]	**Prevention effect of H5N1 HPAI and H1N1 pdm2009 influenza vaccine based on highly attenuated vaccinia virus vector in cynomlgus monkeys** K. Munekata[1], F. Yasui[1], Y. Itoh[2], K. Ishii[3], Y. Sakoda[4], H. Kida[4], K. Ogasawara[2], M. Kohara*[1], *[1]Tokyo Metropolitan Institute of Medical Science, Japan, [2]Shiga University of Medical Science, Japan, [3]National Institute of Infectious Diseases, Japan, [4]Hokkaido University, Japan*
[P1.16]	**Influenza hemagglutinin glycoproteins with different N-glycan patterns activate dendritic cells in vitro** W.C. Liu[1], Y.L. Lin[2], M. Spearman[3], P.Y. Cheng[2], M. Butler[3], S.C. Wu[1], H.H. Lin*[1], *[1]National Tsing Hua University, Taiwan, [2]National Taiwan University Hospital, Taiwan, [3]University of Manitoba, Canada*
[P1.17]	**Immunization of mice with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral and cell-mediated immunity against pneumonic Plague** B.L. Tiner*, J. Sha, Y. Cong, A.K. Chopra, *University of Texas, USA*
[P1.18]	**CovR/S mutant group A streptococcus alter the expression of specific virulence factors to evade vaccine-mediated protection** E.L. Langshaw*, M. Pandey, V. Ozberk, M. Zaman, A. Ssemaganda, A. Calcutt, J. Powell, M.R. Batzloff, M.F. Good, *Griffith University, Australia*
[P1.19]	**Mapping T and B cell epitopes in Dengue Virus E Protein to support the development of Dengue Vaccine design** S. Afzal*, M. Idrees, *University of The Punjab, Lahore, Pakistan*
[P1.20]	**A feasibility study to establish and optimize immune monitoring assays for a first in man study of a therapeutic *h. pylori* vaccine in healthy infected volunteers** K. Straubinger*[1], B. Kalali[1], F. Anderl[1], M. Andree[1], C. Bolz[1], T. Kruse[1], M. Gerhard[1,2], *[1]ImevaX GmbH, Germany, [2]Intstitut für Med. Mikrobiologie, Germany*
[P1.21]	**Highly attenuated vaccinia virus with target inactivated six individual genes** S.N. Shchelkunov*, S.N. Yakubitskyi, I.V. Kolosova, R.A. Maksyutov, *State Research Center of Virology and Biotechnology VECTOR, Russia*
[P1.22]	**Effect of adjuvant formulation on the immunogenicity and protective efficacy of Salmonella Enteritidis Core-OPS (COPS) conjugates with flagellin in adult and infant mice** S.M. Baliban*, G. Ramachandran, R.S. Laufer, M.F. Pasetti, R. Simon, *University of Maryland, USA*
[P1.23]	**Dose-optimal vaccine allocation over multiple populations** L.E. Duijzer*[1], W.L. Van Jaarsveld[2], J. Wallinga[3], R. Dekker[1], *[1]Erasmus University Rotterdam, The Netherlands, [2]Eindhoven University of Technology, The Netherlands, [3]National Institute for Public Health and the Environment, The Netherlands*
[P1.24]	**The most efficient critical vaccination coverage and its equivalence with maximizing the herd effect** L.E. Duijzer*[1], W.L. Van Jaarsveld[2], J. Wallinga[3], R. Dekker[1], *[1]Erasmus University Rotterdam, The Netherlands, [2]Eindhoven University of Technology, The Netherlands, [3]National Insttute of Public Health and the Environment, The Netherlands*
[P1.25]	**Inhalational vaccines for tuberculosis using pharmaceutical preparations: a concept** K. Maniar*, D. Banerjee, A. Patil, A. Chakrabarti, *Post Graduate Institute of Medical Education and Research, India*
[P1.26]	**Both secreted and intracellular forms of HIV-1 reverse transcriptase induce oxidative stress and exhibit similar immunogenicity in DNA-immunized mice** A. Latanova*[1,2], S. Petkov[3], Y. Kuzmenko[1], A. Kilpeläinen[3], A. Ivanov[1], O. Smirnova[1], O. Latyshev[2], J. Hinkula[4], V. Karpov[1], M. Isaguliants[2,5], *[1]Engelhardt Institute of Molecular Biology, Russia, [2]Gamaleja Research Center of Epidemiology and Microbiology, Russia, [3]Karolinska Institutet, Sweden, [4]Linköping University, Sweden, [5]Riga Stradins University, Latvia*
[P1.27]	**In vitro HLA peptide-binding assay improves selection of candidate CD8+ T cell epitopes** J.Y. Mok[1], M. Maas[1], K. Skibbe[2], J. Timm[2], W. van Esch*[1], *[1]Sanquin, The Netherlands, [2]Institute of Virology, Germany*
[P1.28]	**Live recombinant Measles-M2 vaccine induces broad-spectrum protective immunity against influenza viruses** H.H.H. Vo, C. Ruffié, V. Lorin, F. Tangy, N. Escriou*, *Institut Pasteur, France*
[P1.29]	**Overcoming low immunogenicity of reverse transcriptase in therapeutic HIV vaccine design** A. Latanova*[1,2], S. Petkov[3], A. Kilpeläinen[3], O. Latyshev[2], M. Yasuhiro[5], M. Gomelsky[1], M. Isaguliants[2,4], E. Starodubova[1,4], *[1]Engelhardt Institute of Molecular Biology, Russia, [2]Gamaleja Research Center of Epidemiology and Microbiology, Russia, [3]Karolinska Institutet, Sweden, [4]MP Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russia, [5]BEX Co Ltd, Japan, [6]University of Wyoming, USA*
[P1.30]	**Predictive factors related to seasonal Influenza vaccine acceptance among health care workers and students in Iran** S.M. Zahraei*, P. Hodaei, *Center for Communicable Disease Control, Iran*
[P1.31]	**Improving the safety of a whole-influenza-virus vaccine through delipidation** M. Abe*, K. Ikeda, R. Yamaue, I. Asano, H. Onuma, Y. Ohyama, K. Matsuura, H. Mori, K. Kimachi, Y. Kino, *Kaketsuken, Japan*
Immunology / animal models	

[P1.32]	**Development of female mouse model for vaginal infection by S. agalactiae** M.J. Altamirano[1,2], D.A. Soto*[1], Y. Leyton[1], A.M. Vega[5], F. Carrion[5], O. Lopez[4], A.M. Kalergis[2,3], A.E. Vasquez[1,2], *[1]Instituto de Salud Pública de Chile, Chile, [2]Millennium Institute on Immunology and Immunotherapy, Chile, [3]Pontificia Universidad Católica de Chile, Chile, [4]Universidad Santo Tomás, Chile, [5]Universidad de Los Andes, Chile*
[P1.33]	**Vaginal infection - challenge test by candida spp. in rats** J. Nepereny*, V. Vrzal, *Bioveta, a. s., Czech Republic*
[P1.34]	**Host immune responses to mycobacterium tuberculosis antigen Rv34xx** H.S. Park*, S.A. Choi, Y.J. Son, H.G. Choi, H.J. Kim, *Chungnam National University, Republic of Korea*
[P1.35]	**A failure of strain-specific immune induction may underlie the epidemic of streptococcal pyoderma: overcoming immune resistance through vaccination.** M. Pandey*, V. Ozberk, A. Calcutt, E. Langshaw, J. Powell, T. Rivera Hernandez, M. Ho, Z. Philips, M.R. Batzloff, M.F. Good, *Griffith University, Australia*
[P1.36]	**Determination of CMV-specific cell-mediated immunity using T-activated® antigens and an optimized IFN-γ ELISpot assay** S. Barabas[1], T. Spindler[1], C. Tonar[1], T. Widmann[1], A. Rascle[1], J. Batzilla[1], A. Asbach-Nitzsche[1], L. Deml*[1], R. Kiener[2], R. Wagner[2], *[1]Lophius Biosciences, Germany, [2]University Regensburg, Germany*
[P1.37]	**Targeting EBV positive cancers with affinity enhanced T cell receptors** Y. Wong*[1], E. Gostick[2], M.E. Lomax[3], A. Vuidepot[3], E. Baston[3], W. Shingler[3], N. Hassan[3], C. Smith[1], R. Khanna[1], J.J. Miles[1,2], *[1]QIMR Berghofer Medical Research Institute, Australia, [2]Cardiff University School of Medicine, UK, [3]Immunocore Limited, UK*
[P1.38]	**Assessment of outer membrane vesicles of Porphyromonas gingivalis as a mucosal immunogen candidate for development of a periodontal disease vaccine** R. Nakao*, H. Hasegawa, M. Ohnishi, H. Senpuku, *National Institute of Infectious Diseases, Japan*
[P1.39]	**A salmonella typhimurium ghost vaccine induces immune responses and protects rats against homologous and heterologous challenges** N. Vinod, S. Ji, H.J. Park, S. Oh, H.B. Noh, J.M. Koo, S.C. Kim, C.W. Choi*, *Pai Chai University, Republic of Korea*
[P1.40]	**Chemically induced *Vibrio parahaemolyticus* ghosts as a novel vaccine candidate against virulent challenge in a rat model** H.J. Park, N. Vinod, S. Ji, S. Oh*, J.M. Koo, H.B. Noh, K-S. Lee, S.C. Kim, C.W. Choi, *Pai Chai University, Republic of Korea*
[P1.41]	**Biochemical and immunological evaluation of chemically induced *Listeria monocytogens* bacterial ghosts** S. Ji*, S. Oh, N. Vinod, H.J. Park, J.M. Koo, H.B. Noh, K-S. Lee, S.C. Kim, C.W. Choi, *Pai Chai University, Republic of Korea*
[P1.42]	**Immune correlates for VEEV replicon vaccine protection against Ebola virus** S.W. Stonier*, R.M. James, N.M. Josleyn, A.I. Kuehne, R.R. Bakken, J.M. Dye, *United States Army Medical Research Institute of Infectious Diseases, USA*
[P1.43]	**Vaccinia virus E6 protein as a novel antigen for vaccines against orthopoxviruses** S. Santos*, E. Miranda, O. Martínez, M. Ramírez, R. Rodríguez, M. Otero, *University of Puerto Rico-Medical Sciences Campus, Puerto Rico*
[P1.44]	**Human neonatal and adult primary dendritic cells and monocyte-derived dendritic cells show different responses following stimulation with Toll-like receptor ligands – a pitfall in the development of new vaccine formulations?** F. Borgans, L. Pretsch, M. Fichter*, F. Zepp, S. Gehring, V. Saase, *University Medical Center Mainz, Germany*
[P1.45]	**Infection-permissive immunity against influenza virus provided by vaccination prevents loss of alveolar macrophages and modulates virus-induced cross-reactive cellular immune responses during subsequent influenza infections** S.M. Schotsaert*[1], J.A.M.M. Morales Mina[1], J.S. Spitaels[2,3], A.G.S. Garcia-Sastre[1], *[1]Icahn School of Medicine At Mount Sinai, USA, [2]Ghent University, Belgium, [3]VIB, Belgium*
[P1.46]	**Protection and memory immune response against Bordetella parapertussis induced by a whole cell pertussis vaccine with low levels of endotoxin (Plow)** P.S. Cunegundes*, A.F.R.O. Prestes, E.P. Silva, I. Raw, W.O. Dias, *Instituto Butantan, Brazil*

Poster Session 2
Wednesday 7 September 2016
14:30-16:30

Clinical studies and field trials	
[P2.01]	**Bacterial lysate of E.coli stimulates mucosal immunity of the lower urinary tract** E.V. Volkova*[1,2], V.G. Khomenkov[1], E.A. Akhmatova[1], N.K. Akhmatova[1], T.S. Perepanova[1,2], V.V. Zverev[1], O.V. Lebedinskaya[1], *[1]FGBNU Mechnikov Research Institute for Vaccines and Sera, Russia, [2]Lopatkin NA Institute of Urology and Interventional Radiology, Russia*

[P2.02]	**MNRI and bacterial lysates: influence on the innate immunity in patients with microbial eczema** N.K. Akhmatova, E.V. Sorokina, E.A. Akhmatova*, *FGBNU Mechnikov Research Institute for Vaccines and Sera, Russia*
[P2.03]	**The effectiveness of therapeutic vaccines and reflex integration techniques in patients with erythema multiforme** E.A. Akhmatova*[1], E.V. Sorokina[1], E.A. Akhmatov[1], *[1]I.I.Mechnikov Research Institute of Vaccines and Serums, Russia, [2]Svetlana Masgutova Educational Institute for Neuro-Sensory-Motor and Reflex Integration, USA*
[P2.04]	**Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: phase IIb study protocol** E. van Doorn[1], H. Liu*[1], T. Ben-Yedidia[2], S. Hassin[2], I. Visontai[3], S. Norley[4], H. Frijlink[1], E. Hak[1], *[1]University of Groningen, The Netherlands, [2]BiondVax, Israel, [3]National Center for Epidemiology, Hungary, [4]Robert Koch Institute, Germany*
[P2.05]	**The peak titers of antibodies to the surface antigen of hepatitis B virus after vaccination in relation to polymorphisms in the immunity-related genes - a prospective study among hemodialysis patients** E. Jodlowska, A. Mostowska, W. Warchol, P.P. Jagodzinski, A.E. Grzegorzewska*, *Poznan University of Medical Sciences, Poland*
[P2.06]	**Post-vaccination anti-HBs titers and modality of dialysis treatment in uremic patients** A.E. Grzegorzewska*, M.K. Swiderska, W. Warchol, *Poznan University of Medical Sciences, Poland*
[P2.07]	**A cross sectional investigation of parents' perception and practices regarding vaccination** T. Hussain, A. Moin, M.S. Alshammri, A.K. Almoqbel, Y.N. Alsomir, T.J.A. Almutairi, M.H. Aldhafeeri, T.M. Alshammari*, *University of Hail, Saudi Arabia*
	Human vaccines - non-infectious diseases
[P2.08]	**Recurrent infection of the lower urinary tract, Uro-vaxom: impact on the level of blood dendritic cells** N.K. Akhmatova[1], V.G. Khomenkov[1], E.V. Volkova[1,2], E.A. Akhmatova*[1], S.A. Skhodova[1], O.V. Lebedinskaya[1], T.S. Perepanova[1,2], V.V. Zverev[1], *[1]FGBNU Mechnikov Research Institute for Vaccines and Sera, Russia, [2]Lopatkin NA Institute of Urology and Interventional Radiology, Russia*
[P2.09]	**A cellular system for the assessment of IgE-BCR Receptor crosslinking by monoclonal or vaccine-induced antibodies** B. Vigl*, N. Salhat, M. Parth, H. Pankevych, A. Mairhofer, A. von Bonin, O. Smrzka, *AFFiRiS AG, Austria*
	Other
[P2.10]	**S. agalactiae disrupt the integrity of an in vitro model of human blood-brain barrier injuring Tight Junctions proteins** Y. Leyton[1], E. Eugenin[2], M.J. Altamirano[1,4], D.A. Soto[1], A.M. Kalergis[3,4], A.E. Vasquez*[1,3], *[1]Instituto de Salud Pública de Chile, Chile, [2]The Public Health Research Institute Center, USA, [3]Millennium Institute on Immunology and Immunotherapy, Chile, [4]Pontificia Universidad Católica de Chile, Chile*
[P2.11]	**Gingival vaccination for the elderly population** M. Cueno*, M. Tamura, K. Imai, *Nihon University, Japan*
[P2.12]	**A consolidation phase in immune memory** F. Mantile[1], A. Capasso[1], P. De Berardinis[2], M. Nicodemi[3], A. Prisco*[1], *[1]Institute of Genetics and Biophysics, Italy, [2]Institute of Protein Biochemistry, Italy, [3]Università degli studi di Napoli, Italy*
	Production / manufacturing
[P2.13]	**Modifications induced by formaldehyde: direct comparison between tetanus toxin and toxoid** C. Bayart*[1,2], S. Peronin[2], E. Jean[2], J. Paladino[2], P. Talaga[2], M. Le Borgne[1], *[1]Université Claude Bernard Lyon 1, France, [2]Sanofi Pasteur, France*
	Regulatory / societal / economic / programmatic / legislation subjects
[P2.14]	**Factors influencing children's engagement in the rabies post-exposure prophylaxis: a qualitative study** Y.M. Marpaung*, C. Wentink, *Wageningen University, The Netherlands*
[P2.15]	**A systematic review of vaccine hesitancy towards malaria vaccination in sub-saharan africa: are communities willing to have their children vaccinated against malaria** S.L. Patterson*, T.J. Patterson, *Queen's University Belfast, UK*
[P2.16]	**Suboptimal under one year-old vaccination coverage in South African children with diarrhoea attending a tertiary hospital in Gauteng Province in 2011-2014** R.J. Burnett[1], G. Mmoledi[2], C. Dochez*[1], L.M. Seheri[2], M.J. Mphahlele[1,2], *[1]Sefako Makgatho Health Sciences University, South Africa, [2]University of Antwerp, Belgium*
[P2.17]	**Classification of parent attitudes about childhood vaccines using machine learning techniques** L. Del Rio*, A. Maurandi-Lopez, J.A. Palazon, A. González-Vidal, M.D. Perez-Cárceles, *University of Murcia, Spain*
[P2.18]	**Perceptions and beliefs of parents from a rural district in KwaZulu-Natal, South Africa regarding pneumococcal disease vaccination - a qualitative study** P.X. Ndlovu[1], J.C. Meyer*[1,2], N. Schellack[1], *[1]Sefako Makgatho Health Sciences University, South Africa, [2]South African Vaccination and Immunisation Centre, South Africa*

[P2.19]	**Should India introduce conditional cash transfers to improve equity in the coverage of universal immunization programme: a scoping study** M. Grover*, L. Kant, *Public Health Foundation of India, India*
	Vaccine safety
[P2.20]	**Post-licensure observational safety study of quadrivalent meningococcal ACWY conjugate vaccine MenACWY-CRM (Menveo) in children 2 through 10 years of age** H. Tseng[1], L. Sy[1], B. Ackerson*[2], R. Hechter[1], S. Tartof[1], M. Haag[3], J. Slezak[1], Y. Luo[1], C. Fischetti[1], H. Takhar[1], *[1]Kaiser Permanente Southern California, USA, [2]Southern California Permanente Medical Group, USA, [3]Seqirus, The Netherlands, [4]GlaxoSmithKline, The Netherlands*
[P2.21]	**Characterization of mosquito and mammalian cells persistently co-infected with Rift Valley fever virus MP-12 strain and the genetic variant** H.J. Ly*, N. Lokugamage, T. Ikegami, *The University of Texas, USA*
	Vectors / adjuvants / drug delivery
[P2.22]	**Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture** Y-H. Chow, *Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Taiwan*
[P2.23]	**Physicochemical and biological characterisation of emulsion-based nanoadjuvants and their potentials in formulation of new generation vaccines.** A. Razim*[1], S. Górska[1], M.A. Olszewski[2], A. Gamian[1], A. Myc[1,3], *[1]Polish Academy of Sciences, Poland, [2]University of Michigan Medical School, USA, [3]University of Zielona Gora, Poland*
[P2.24]	**Biomimetically engineered demi-bacteria potentiate vaccination against cancer** W. Wei*, D.Z. Ni, S. Qing, H. Yue, G.H. Ma, *Institute of Process Engineering, Chinese Academy of Sciences, China*
[P2.25]	**Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles** M.L.M. Salverda*[1], S. Meinderts[1], H.J. Hamstra[2], A. Wagemakers[3], J.W. Hovius[3], A. van der Ark[1], M. Stork[1], P. van der Ley[1], *[1]Intravacc, The Netherlands, [2]RIVM, The Netherlands, [3]AMC, The Netherlands*
[P2.26]	**$CaCO_3$-based nano-missile potentiates antigen delivery and cross-presentation** S. Wang*, H. Yue, X.B. Xi, W. Wei, G.H. Ma, *Institute of Process Engineering, Chinese Academy of Sciences, China*
[P2.27]	**Using self-healing microcapsules as antigen arsenal to elicit a prolonged anti-tumor response** X. Xi*, X. Na, S. Wang, W. Wei, G. Ma, *State Key Laboratory of Biochemical Engineering, Institute of process engineering, chinese academy of sciences, China*
[P2.28]	**The mycobacterial cell-wall skeleton is for tuberculosis vaccine adjuvant that induces a strong Th1 and Th17 immune response.** Y.W. Baek*, H.J. Kim, *Chungnam National University, Republic of Korea*
[P2.29]	**Integration of O/W emulsion and particulate adjuvant acts as elastic particulate antigen delivery system to induce robust T-cell-mediated responses** Y. Xia*[1,2], J. Wu[1], G. Ma[1], Z. Su[1], *[1]Institute of Process Engineering, Chinese Academy of Sciences, China, [2]University of Chinese Academy of Sciences, China*
[P2.30]	**Dual effect of TLR9L on the priming of human CD8+ T cell responses** F. Nicoli*, L. Papagno, A. Lissina, V. Appay, *Sorbonne Universités, France*
[P2.31]	**Towards the development of a novel intranasal vaccine for group A streptococcus upper respiratory tract infections** V. Ozberk*[1], M. Zaman[1], E.L. Langshaw[1], A. Calcutt[1], J. Powell[1], M.R. Batzloff[1], J. Dietrich[2], M. Pandey[1], M.F. Good[1], *[1]Griffith University, Australia, [2]Staten Serum Institut, Denmark*
[P2.32]	**Interest of flagellin FliC in mucosal vaccination against clostridium difficile** J-F. Bruxelle*[1], A. Mizrahi[1,2], S. Hoys[1], A. Collignon[1], C. Janoir[1], S. Péchiné[1], *[1]Université Paris-Saclay, France, [2]Groupe hospitalier Paris Saint Joseph, France*
[P2.33]	**Molecular immune adjuvant B-cell activating factor (BAFF) enhances antibody responses to DNA vaccines** S. Agarwal*, S. Kudchodkar, E. Reuschel, K. Muthumani, D. Weiner, *The Wistar Institute, USA*
[P2.34]	**A recombinant lipoprotein-based subunit vaccine approach is powerful to induce robust cellular and humoral immune responses in the absent of exogenous adjuvant formulation** H.W. Chen*, S.J. Liu, P. Chong, C.H. Leng, *National Health Research Institutes, Taiwan*
[P2.35]	**Adjuvant activity of probiotic Bacillus subtilis spores for mucosal route delivery** F. Tub-Chafer[3], L.M. Reyes Díaz[4], I.G. Vega García[3], E. González Aznar[4], O. Otero Alfaro[4], J. Lumpuy Castillo[3], M. Lastre González[3], R. Grau*[1,2], O. Perez[3], *[1]Universidad Nacional de Rosario, Argentina, [2]CONICET, Argentina, [3]Universidad de Ciencias Médicas de la Havana, Cuba, [4]Instituto Finlay, Cuba*
[P2.36]	**Polymeric hepatitis C virus non-structural protein 5A nanocapsules induce intrahepatic antigen-specific immune responses** M. Fichter*[1], K. Piradashvili[2], A. Pietrzak-Nguyen[1], L. Pretsch[1], G. Kuhn[1,2], S. Strand[1], M. Knuf[3,1], F. Zepp[1], F. Wurm[2], V. Mailänder[1,2], *[1]University Medical Center Mainz, Germany, [2]Max Planck Institute for Polymer Research Mainz, Germany, [3]Dr. Horst-Schmidt-Kliniken Wiesbaden, Germany*

[P2.37]	**Adjuvant activity of saponin and chitosan for oral viral hemorrhagic septicemia virus vaccine** M-H. Jung*, S-J. Jung, *Chonnam National University, Republic of Korea*
[P2.38]	**Hepatitis b antigen: adjuvant activity of polycaprolactone/chitosan particles characterized by mast cell activation, interferon-γ and interleukine-17 production** S. Jesus[1], E. Soares[1], G. Borchard[2], O. Borges*[1], *[1]University of Coimbra, Portugal, [2]University of Geneva, Switzerland*
Veterinary vaccines	
[P2.39]	**Comparison of subcutaneous and intradermal immunization of dogs against rabies** V. Vrzal*, J. Nepereny, *Bioveta, a.s., Czech Republic*
[P2.40]	**Immunogenicity of pure low volume of inactivated Influenza H9N2-Newcastle vaccine** A. Nazari Shirvan*, M. Samianifard, N. Ghodsian, I. Khalili, G. Hanifi, *Razi Vaccine & Serum Research Institute, Iran*
[P2.41]	**Effective stabilization of a live viral vaccine by lyophilized and liquid SPS® formulations - example of a PRRSV vaccine in animal health** M. Scholz, T. Kriehuber*, R. Derwand, J. Altrichter, *LEUKOCARE AG, Germany*
[P2.42]	**Monovalent H5 vaccine based on epitope-chimeric HA provides broadcross-clade protection against variant H5N1 viruses in mice** F. He*[1,2], J. Kwang[2], *[1]Zhejiang University, China, [2]Temasek Life Sciences Laboratory, Singapore*
[P2.43]	**Protective immunity against rock bream iridovirus (RBIV) following CpG ODN administration** M-H. Jung*, S-J. Jung, *Chonnam National University, Republic of Korea*
[P2.44]	**Efficacy mechanism of squalene and aluminium hydroxide adjuvanted viral haemorrhagic septecemia virus (VHSV) vaccine** S-J. Jung*, T-N. Viany, J-W. Ryu, M-H. Jung, *Chonnam National University, Republic of Korea*
[P2.45]	**Protection of khaki campbell ducks from fowl cholera by vaccination with an intranasal fowl cholera vaccine** N. Sthitmatee*[1], P. Poolperm[1], Y. Kataoka[2], T. Sawada[2], *[1]Chiang Mai University, Thailand, [2]Nippon Veterinary and Life Science University, Japan*
[P2.46]	**Cross protection conferred by immunization with a rOmpH-based intranasal fowl cholera vaccine in layers** T. Varinrak*[1], P. Poolperm[1], T. Sawada[2], N. Sthitmatee[1], *[1]Chiang Mai University, Thailand, [2]Nippon Veterinary and Life Science University, Japan*
[P2.47]	**Protection conferred by immunization with an in-house intranasal hemorrhagic septicemia vaccine in dairy cattle** P. Tankaew*[1], K. Muangthai[2], R. Uthi[2], S. Rojanasthien[1], T. Sawada[3], N. Sthitmatee[1], *[1]Chiang Mai University, Thailand, [2]Bureau of Veterinary Biologics, Thailand, [3]Nippon Veterinary and Life Science University, Japan*
Virus and VLP Bioprocessing	
[P2.48]	**Development of an integrated process for an HCV vaccine candidate production** H.R. Soares*[1,2], S.B. Carvalho[1,2], M. Ferreira-Fernandes[1,2], P. Gomes-Alves[1,2], C. Peixoto[1,2], P.M. Alves[1,2], M.J.T. Carrondo[1,3], A.S. Coroadinha[1,2], *[1]iBET, Portugal, [2]ITQB, Portugal, [3]FCT-NOVA, Portugal*
[P2.49]	**Cell-based biosensors for detection and quantification of label-free virus for research and diagnostics** M.R. Guerreiro*[1,2], A.F. Rodrigues[1,2], P.M. Alves[1,2], A.S. Coroadinha[1,2], *[1]Instituto de Biologia Experimental e Tecnológica, Portugal, [2]Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Portugal*